# Genocury Biotech

Source: https://onco.cc/companies/genocury-biotech/  
OnCo record `genocury-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Genocury Biotech, in Shenzhen, is testing CAR-T treatments made inside the patient's body from a single infusion, rather than in a laboratory, for lymphoma, leukaemia and myeloma. The trials are early and run by hospital investigators in China.

## Summary

Shenzhen Genocury Biotech develops in vivo CAR-T therapies: an intravenous product that generates CAR-T cells inside the body. On ClinicalTrials.gov it sponsors investigator-initiated, single-centre studies of JY231 in relapsed or refractory B-cell lymphoma and leukaemia (NCT06678282, started 2023; NCT06890065, started 2025) and of JY232 in relapsed or refractory multiple myeloma (NCT07336823, registered January 2026). In April 2025 the company reported a single case from an investigator-initiated trial at Tongji Hospital: a patient with relapsed or refractory diffuse large B-cell lymphoma reached complete remission within 28 days of one dose of its in vivo CD19 CAR-T, given without lymphodepleting chemotherapy, with no cytokine release syndrome or ICANS reported. That is one patient. OrbiMed's portfolio page describes the company as developing in vivo CAR-T for oncology and autoimmune diseases. Its website also lists iPSC and reporter cell-line services.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Shenzhen Genocury Biotech Co., Ltd.; 济因生物; Genocury
- HQ: Shenzhen
- Type: cell-therapy
- Website: https://genocury.com/

## Notes

- Founding year not stated on a source read.
- The April 2025 release does not name the product; whether JY231 is the CD19 product described is not stated, so the CD19 target is from the release and not from the registry.
- The website's pipeline page loads from an API and could not be read as text; HQ is the Shenzhen address in the site footer.
- None of the three Genocury trials has an OnCo trial record. ClinicalTrials.gov lists phase 'not applicable' for the JY231 studies and early phase 1 for JY232.

## Sources

- Official website (Chinese): https://genocury.com/
- JY231 trial NCT06678282: https://clinicaltrials.gov/study/NCT06678282
- April 2025 DLBCL case release (1stOncology): https://www.1stoncology.com/blog/?p=102826
- OrbiMed portfolio entry: https://www.orbimed.com/portfolio/

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [JY231](https://onco.cc/drugs/jy231/), [JY232](https://onco.cc/drugs/jy232/)
- companies: [OrbiMed](https://onco.cc/companies/orbimed/)
- trials: [JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia](https://onco.cc/trials/nct06678282/), [JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia](https://onco.cc/trials/nct06890065/), [JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct07336823/)

---
JSON: https://onco.cc/api/v1/entities/genocury-biotech.json